Table 1.
The baseline demographics and disease characteristics of 62 Chinese patients with advanced NSCLC and 2nd-line chemotherapy of nintedanib
| Number | Percentage | |
|---|---|---|
| Sex | ||
| Male | 31 | 50.0% |
| Female | 31 | 50.0% |
| Age (years) | ||
| Median | 64.2 | |
| Range | 33-83 | |
| ≥ 60 years | 45 | 72.6% |
| ECOG Performance Status | ||
| 0 | 11 | 17.7% |
| 1 | 39 | 62.9% |
| 2 | 12 | 19.4% |
| Smoking History | ||
| Current or ex-smoker | 39 | 62.9% |
| Never | 23 | 37.1% |
| NSCLC sub-type | ||
| Adenocarcinoma | 35 | 56.5% |
| Squamous carcinoma | 17 | 27.4% |
| Large carcinoma | 6 | 9.7% |
| Other | 4 | 6.5% |
| Time since 1st-line chemotherapy (months) | ||
| ≤ 2 | 42 | 67.7% |
| > 2 | 20 | 32.3% |
| Response to 1st-line chemotherapy | ||
| Complete response | 0 | 0.0% |
| Partial response | 11 | 17.7% |
| Stable disease | 38 | 61.3% |
| Progressive disease | 13 | 21.0% |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.